Boston Scientific Files 8-K with Updates
Ticker: BSX · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0000885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, exhibits
Related Tickers: BSX
TL;DR
BSX filed an 8-K on 3/30/26, check exhibits for news.
AI Summary
Boston Scientific Corporation filed an 8-K on March 30, 2026, reporting other events and financial statements. The filing includes press releases as exhibits, indicating potential significant corporate announcements or updates. The company's mailing and business address is 300 Boston Scientific Way, Marlborough, MA 01752.
Why It Matters
This 8-K filing by Boston Scientific could contain material information impacting investors and the medical device industry. Investors should review the exhibits for specific details.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting other events and exhibits, without immediate indication of significant financial distress or major operational changes.
Key Players & Entities
- Boston Scientific Corporation (company) — Filer
- 0000885725 (company) — CIK
- 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 (location) — Mailing and Business Address
- 2026-03-30 (date) — Filing Date
- 2026-03-28 (date) — Period of Report
FAQ
What specific events are detailed in the 8-K filing?
The filing is categorized under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), suggesting it contains announcements or updates beyond standard financial reporting, with press releases provided as exhibits.
When was this 8-K filing accepted by the SEC?
The 8-K filing was accepted by the SEC on March 30, 2026.
What is Boston Scientific Corporation's CIK number?
Boston Scientific Corporation's CIK number is 0000885725.
What are the included exhibits with this 8-K filing?
The filing includes exhibits such as EX-99.1 and EX-99.2, identified as press releases, along with XBRL documents.
What is the primary business of Boston Scientific Corporation based on the SIC code?
Based on the SIC code 3841, Boston Scientific Corporation's primary business is in Surgical & Medical Instruments & Apparatus.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2026-03-30 06:14:18
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock
Filing Documents
- bsx-20260328.htm (8-K) — 29KB
- ex991-pressrelease.htm (EX-99.1) — 19KB
- ex992-pressrelease.htm (EX-99.2) — 25KB
- image_0a.jpg (GRAPHIC) — 37KB
- 0000885725-26-000029.txt ( ) — 288KB
- bsx-20260328.xsd (EX-101.SCH) — 3KB
- bsx-20260328_def.xml (EX-101.DEF) — 15KB
- bsx-20260328_lab.xml (EX-101.LAB) — 27KB
- bsx-20260328_pre.xml (EX-101.PRE) — 16KB
- bsx-20260328_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On March 28, 2026, Boston Scientific Corporation (the "Company") issued a press release announcing results from the Company's HI-PEITHO clinical trial. Also on March 28, 2026, the Company issued a second press release announcing results from the Company's CHAMPION-AF clinical trial. Copies of each press release are included as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference; provided, however, that information on or connected to the Company's website or the website of any third-party hyperlinked from or referenced in the press releases included as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 28 , 202 6 . 99.2 Press Release, dated March 28 , 202 6 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 30, 2026 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary